Insider · CIK 0001865633
Brian Burkavage
Files at IOBT (IO Biotech, Inc.). First filing Nov 24, 2023, latest Nov 24, 2023.
In brief
Brian Burkavage files SEC Form 4 as officer at IOBT (IO Biotech, Inc.). Since Nov 24, 2023, Brian Burkavage has reported 1 open-market buy worth $10k and 0 open-market sells worth $0, the latest filed on Nov 24, 2023.
A track record needs three past buys with six months of prices behind them; Brian Burkavage has 0, so none is measured yet.
The newest scored trade: bought $10k of IOBT on Nov 21, 2023, filed Nov 24, 2023, scored 25 (weak).
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 2, 2025 | IOBT IO Biotech, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Apr 4, 2025 |
| Mar 15, 2024 | IOBT IO Biotech, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 18, 2024 |
| Nov 21, 2023 | IOBT IO Biotech, Inc. | POpen-market purchase Common Stock | +5,000 | $0.99 | $4,950 | 6,500 | Nov 24, 2023 |
| Nov 22, 2023 | IOBT IO Biotech, Inc. | POpen-market purchase Common Stock | +5,000 | $1.04 | $5,175 | 11,500 | Nov 24, 2023 |
Questions about Brian Burkavage
Answered from the filings on this page, as of the latest one.
Is Brian Burkavage buying or selling?
Not in the last 12 months. Brian Burkavage's latest open-market trade on SEC Form 4 was bought $10k of IOBT on Nov 21, 2023.
How did Brian Burkavage's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Brian Burkavage has 0.
Where does Brian Burkavage file Form 4?
Brian Burkavage has filed Form 4 at IOBT (IO Biotech, Inc.) as Chief Accounting Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.